KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $173.4 million.

  • BioNTech SE's Cost of Revenue fell 1175.77% to $173.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $608.2 million, marking a year-over-year increase of 1746.5%. This contributed to the annual value of $578.4 million for FY2024, which is 1036.93% down from last year.
  • BioNTech SE's Cost of Revenue amounted to $173.4 million in Q3 2025, which was down 1175.77% from $86.5 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Cost of Revenue ranged from a high of $1.5 billion in Q1 2022 and a low of $64.2 million during Q1 2024
  • Over the past 5 years, BioNTech SE's median Cost of Revenue value was $192.7 million (recorded in 2023), while the average stood at $433.6 million.
  • Over the last 5 years, BioNTech SE's Cost of Revenue had its largest YoY gain of 431695433526.1% in 2021, and its largest YoY loss of 9999.86% in 2021.
  • Over the past 5 years, BioNTech SE's Cost of Revenue (Quarter) stood at $667.2 million in 2021, then tumbled by 71.94% to $187.2 million in 2022, then rose by 2.93% to $192.7 million in 2023, then soared by 35.03% to $260.2 million in 2024, then crashed by 33.37% to $173.4 million in 2025.
  • Its Cost of Revenue stands at $173.4 million for Q3 2025, versus $86.5 million for Q2 2025 and $88.1 million for Q1 2025.